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Abstract. Background: Atrial fibrillation (AF) is the
most common sustained arrhythmia and various AF dis-
ease management strategies can be utilized.
Methods: A prospective, randomized pilot study of two
AF disease management strategies was conducted at a
single university hospital in patients newly diagnosed
with AF. The impact of low molecular weight heparin
(LMWH) on AF management strategies is discussed with
respect to the current guidelines for AF management,
existing data on LMWH for AF, and recent investiga-
tions pertaining to AF.
Results: 18 patients were enrolled. The accelerated
emergency department based strategy utilizing LMWH
resulted in a significant reduction in length of stay (2.1
± 2.3 versus <1 day) and a trend toward lower costs
($1,706 ± 1,512 versus $879 ± 394; p = 0.15) when com-
pared to the more traditional strategy of hospital admis-
sion. Measured clinical outcomes were similar for both
treatment strategies.
Conclusions: The investigation showed that an out-
patient, emergency department based disease manage-
ment strategy for new, uncomplicated AF could result
in clinically acceptable, cost-effective innovations in AF
treatment strategies. LMWH is an example of an agent
allowing innovations in disease management strategies.
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Introduction
Atrial fibrillation (AF) is the most common sustained
arrhythmia and will become more prevalent with the
aging of the population [1]. The management strat-
egy for this condition on both an individual clini-
cian and health system organization level at the time
of initial hospital presentation is controversial and
there is wide practice variation. Because of the asso-
ciation of AF with cardiovascular complications and
stroke, the choice of management strategy could have
a profound impact on the economics of AF disease
management.
A prospective, randomized pilot study of two AF
disease management strategies was conducted at
a single university hospital in low-risk individuals
with newly diagnosed or new-onset AF [2]. This in-
vestigation compared a traditional strategy of hos-
pital admission versus an accelerated emergency
department based clinical pathway that utilized a
low molecular weight heparin (LMWH), dalteparin,
and early cardioversion to sinus rhythm. Trans-
esophageal echocardiography was used prior to car-
dioversion in selected patients in accordance with
clinical guidelines [3]. The study population con-
sisted of 18 patients randomized over a 15 month
period who presented to the emergency department
with uncomplicated newly diagnosed or new-onset
AF who had no indication for hospital admission
other than AF and were candidates for anticoagula-
tion. The primary endpoints were length of stay and
total actual direct costs.
The accelerated emergency department based
strategy was associated with a significant reduction
in length of stay (2.1 ± 2.3 versus <1 day) and a trend
toward lower costs ($1,706 ± $1,512 versus $879 ±
$394; p = 0.15). Measured clinical outcomes (rate of
sinus rhythm at discharge and one month follow-up
and AF-related complications) were similar for both
treatment strategies. Dalteparin was used to facil-
itate early treatment and discharge in all the ac-
celerated emergency department strategy patients.
The mean number of dalteparin doses was 6.2 ± 4.3,
which was nearly 40% of the total actual direct cost
for this strategy. More direct current cardioversion
procedures were performed with the emergency de-
partment based strategy due to less time allowed for
spontaneous AF conversion.
In summary, the investigation [2] showed that
an outpatient, emergency department based disease-
management strategy for new, uncomplicated AF
could result in clinically acceptable, cost-effective in-
novations in AF treatment strategies. LMWH is an
example of an agent allowing innovations in disease
management strategies.
Data on LMWH for AF: “Fact and Fiction”
The data are clear that warfarin anticoagulation re-
duces the risk of stroke in patients with AF who have
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risk factors for thromboembolism and that warfarin
therapy is superior to aspirin in high-risk individu-
als [3–5]. Nevertheless, prophylactic warfarin for the
prevention of thromboembolism and stroke in AF pa-
tients is grossly underutilized in clinical practice for
a variety of reasons [5]. Given the practical limita-
tions of warfarin therapy, novel anticoagulants such
as oral direct thrombin inhibitors, antiplatelet com-
binations, and left atrial appendage occlusion devices
are under investigation or development [5]. The role
of LMWH in AF has followed an analogous course to
these potential replacements for traditional antico-
agulants like heparin and warfarin, especially in the
areas of disease management in the inpatient setting
and peri-cardioversion facilitation.
Unfractionated heparin and warfarin have been
the mainstays of anticoagulant therapy for many
years. These agents are commonly used in the ini-
tial stages of anticoagulation for short-term med-
ical management and subsequently the long-term
prevention of thromboembolism. However, in recent
years data on the use of LMWH for the treatment
of venous thromboembolism and acute coronary syn-
dromes have demonstrated it’s clinical efficacy and
ease of use [6]. LMWH is increasingly being used
as a protective anticoagulant for AF, mainly to re-
place unfractionated heparin, perhaps in part to de-
crease the hospital length of stay [7,8]. This prac-
tice pattern of LMWH use in AF exists despite
minimal data as to the efficacy or safety of this
strategy.
Early reports of LMWH use in AF noted the ben-
efit of LMWH for thromboprophylaxis in comparison
to no specific therapy [9] and in patients intolerant
of warfarin [10]. More recent studies have shown
that LMWH (dalteparin) could be successfully used
to minimize stroke risk during cardioversion of AF in
patients without previous anticoagulation who have
no thrombus on transesophageal echocardiography
[11]. Other preliminary reports noted the potential
cost-effectiveness of using LMWH (dalteparin) in
outpatient AF management when compared to more
traditional admission for intravenous heparin until
therapeutic levels of warfarin are achieved [12] and
the non-inferiority and safety of LMWH (enoxaparin)
in the process of AF cardioversion, predominantly
via a transesophageal echocardiography guided ap-
proach [13].
The conventional approach [3,14] to the cardiover-
sion of AF with warfarin is based on nonrandomized
studies that showed fewer complications in warfarin
treated patients. Despite the limitations of such data,
this conventional anticoagulant approach is widely
accepted due to historical safety data available back
to the 1960’s [15,16]. The conventional approach
has also compared favorably to the transesophageal
echocardiography guided strategy with an essen-
tially equivalent stroke risk with cardioversion re-
gardless of chosen AF cardioversion strategy [17].
Both the conventional and transesophageal echocar-
diography guided strategy for cardioversion of AF are
accepted standards. The use of LMWH rather than
unfractionated heparin as a bridge to warfarin an-
ticoagulation for cardioversion of AF remains unset-
tled. Clearly, there may be benefits to LMWH from
a cost perspective if the transesophageal echocar-
diography guided approach is chosen [18] and a
reduction in admission rates by allowing outpa-
tient based AF management for low-risk individu-
als. Much needed clarification of the role of LMWH in
transesophageal echocardiography guided cardiover-
sion will come from the Assessment of Cardioversion
Using Transesophageal Echocardiography (ACUTE)
II Study [19] and the Anticoagulation in Cardiover-
sion using Enoxaparin (ACE) Study [20], both of
which will be comparing LMWH versus intravenous
heparin strategies.
LMWH for AF: “Future”
LMWH and novel anticoagulants, in general, will
continue to impact and alter AF disease manage-
ment strategies. The AFFIRM Trial [21] showed that
a strategy of rate control and rhythm control in the
presence of warfarin anticoagulation are both rea-
sonable strategies in AF. Nevertheless, cardioversion
of AF will continue to be an important clinical entity
due to symptomatic AF and potential patient prefer-
ence for sinus or “normal” rhythm. Furthermore, the
data from AFFIRM cannot necessarily be extrapo-
lated to younger AF patients or certain subsets of
AF, such as new-onset or newly diagnosed AF. It is
not entirely clear that the risk of stroke can be re-
duced by restoring sinus rhythm [21,22], but data
from the AFFIRM stroke substudy suggest that the
continued presence of AF increases stroke risk and
the use of warfarin reduces such risk regardless of
AF management strategy [23].
The use of LMWH for cardioversion of AF should
expedite cardioversion similar to intravenous hep-
arin with the possible added benefit of avoiding hos-
pital admission and reducing costs in a significant
number of patients. Outpatient management of AF
will become more common as more data show that
certain subgroups of AF patients can be safely man-
aged without hospitalization [2,24–26]. There may
also be an increased likelihood of maintaining sinus
rhythm with earlier cardioversion, although data
conflict [11,17,27]. Although warfarin without any
form of heparin can be used in patients not requir-
ing admission, the time required to actually satisfy
the current anticoagulation recommendations [3,14]
prior to cardioversion is often longer than 3 to 4
weeks due to the time required to reach the initial
therapeutic INR and the frequency of subtherapeu-
tic INR values following the initial therapeutic value
[28]. This prolonged time to cardioversion should be
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considered when formulating disease management
based approaches to AF.
In summary, there is a promising future for
LMWH in AF disease management for both low and
high risk patients. LMWH has a favorable pharmo-
cologic profile, is easy to use, requires little to no
monitoring, has potential economic benefits, and has
broad flexibility in clinical (inpatient/outpatient) ap-
plications. Clearly, the use of LMWH for AF is ex-
panding for these reasons despite the paucity of data
from controlled clinical trials. We suspect that this
trend will continue, but hopefully in tandem with
more investigational data. Nevertheless, at the cur-
rent time, caution should be exercised in the use of
LMWH for AF since minimal data on efficacy and
safety exist. Furthermore, it is not clear that all
“LMWH” are equal from a therapeutic standpoint
[29]. Future novel anticoagulants will allow innova-
tive and perhaps more cost-effective AF management
strategies. Most promising, other than the LMWH,
are the oral direct thrombin inhibitors, such as Xime-
lagatran, a potential LMWH and warfarin substi-
tute [5]. In addition to the stroke prevention trials
of Ximelagatran, additional safety and efficacy data
for cardioversion of AF will be needed to fully inte-
grate such a new agent into AF disease management
strategies.
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